HSPA5 and brain neoplasm: Cell surface GRP78 inhibition with systemic dosing of GRP78 inhibitors, in preclinical orthotopic brain tumor mouse models, demonstrated significant increases in overall survival and durable regressions in 40 to 70% of treated mice compared to control mice.